

Onno Akkerman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/305617/publications.pdf>

Version: 2024-02-01

112
papers

2,876
citations

236833

25
h-index

206029

48
g-index

117
all docs

117
docs citations

117
times ranked

2652
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0182921.	1.4	4
2	Practices of therapeutic drug monitoring in tuberculosis: an international survey. <i>European Respiratory Journal</i> , 2022, 59, 2102787.	3.1	11
3	Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis. <i>Pharmaceutics</i> , 2022, 14, 753.	2.0	9
4	Optimising tuberculosis care for refugees affected by armed conflicts. <i>Lancet Respiratory Medicine</i> , 2022, 10, 533-536.	5.2	3
5	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	1.5	18
6	Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	3
7	The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1047-1049.	2.8	2
8	Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
9	Clinical standards for the dosing and management of TB drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 483-499.	0.6	22
10	Clinical standards for drug-susceptible pulmonary TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 592-604.	0.6	6
11	The pharmacokinetics of antibiotics in cystic fibrosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 53-68.	1.5	34
12	Tuberculosis Patient-Centred Care. , 2021, , 177-183.		0
13	Assessment of TB treatment on patient well-being. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 315-317.	0.6	2
14	The long-term safety of chronic azithromycin use in adult patients with cystic fibrosis, evaluating biomarkers for renal function, hepatic function and electrical properties of the heart. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 959-963.	1.0	3
15	Shortening MDR-TB treatment: is treating more patients with fewer drugs better?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 419-420.	0.6	2
16	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. <i>Pulmonology</i> , 2021, 27, 403-412.	1.0	30
17	Recurrent fever 3 years post-lung transplantation: A treacherous case of <i>Mycobacterium genavense</i> . <i>Transplant Infectious Disease</i> , 2021, 23, e13741.	0.7	1
18	Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. <i>Frontiers in Immunology</i> , 2021, 12, 725447.	2.2	25

#	ARTICLE	IF	CITATIONS
19	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 797-813.	0.6	78
20	Evaluation of whole-genome sequence data analysis approaches for short- and long-read sequencing of <i>Mycobacterium tuberculosis</i> . <i>Microbial Genomics</i> , 2021, 7, .	1.0	13
21	Malnutrition assessment methods in adult patients with tuberculosis: a systematic review. <i>BMJ Open</i> , 2021, 11, e049777.	0.8	4
22	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 55, 1901908.	3.1	11
23	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	2.0	133
24	Hope rises out of despair: bedaquiline and linezolid for the treatment of drug-resistant TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 987-988.	0.6	2
25	Colistin dry powder inhalation with the Twincerâ„¢: An effective and more patient friendly alternative to nebulization. <i>PLoS ONE</i> , 2020, 15, e0239658.	1.1	11
26	The importance of knowing why TB patients stop anti-TB treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 989-990.	0.6	2
27	Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. <i>European Respiratory Journal</i> , 2020, 56, 2000803.	3.1	8
28	Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data. <i>European Respiratory Journal</i> , 2020, 56, 2001086.	3.1	3
29	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. <i>BMJ Open</i> , 2020, 10, e035350.	0.8	4
30	Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. <i>International Journal of Infectious Diseases</i> , 2020, 92, S10-S14.	1.5	20
31	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. <i>International Journal of Infectious Diseases</i> , 2020, 92, S5-S9.	1.5	13
32	Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. <i>European Respiratory Journal</i> , 2020, 55, 1901903.	3.1	12
33	Corticosteroid therapy for the management of paradoxical inflammatory reaction in patients with pulmonary tuberculosis. <i>Infection</i> , 2020, 48, 641-645.	2.3	4
34	Eradication of <i>Pseudomonas aeruginosa</i> in cystic fibrosis patients with inhalation of dry powder tobramycin. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662090527.	1.0	8
35	Patients and Medical Staff Attitudes Toward the Future Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries Evaluated using a Qualitative Framework. <i>JMIR MHealth and UHealth</i> , 2020, 8, e18156.	1.8	5
36	Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic review. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 811-819.	0.6	31

#	ARTICLE	IF	CITATIONS
37	Performance of a web-based application measuring spot quality in dried blood spot sampling. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1846-1853.	1.4	14
38	Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005–2015. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 115.	1.5	20
39	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	3.1	113
40	Impact of radiographic screening of >34€Š000 asylum seeker children. <i>European Respiratory Journal</i> , 2019, 54, 1900579.	3.1	4
41	Sensitivity and specificity of an electronic nose in diagnosing pulmonary tuberculosis among patients with suspected tuberculosis. <i>PLoS ONE</i> , 2019, 14, e0217963.	1.1	24
42	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	1.5	41
43	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	19
44	Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. <i>European Respiratory Journal</i> , 2019, 54, 1900373.	3.1	7
45	Tuberculosis-Related Malnutrition: Public Health Implications. <i>Journal of Infectious Diseases</i> , 2019, 220, 340-341.	1.9	19
46	Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 834-834.	1.3	1
47	Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands. <i>European Respiratory Journal</i> , 2019, 54, 1901402.	3.1	11
48	Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300€Š...mg linezolid dosages using in-house made capsules. <i>European Respiratory Journal</i> , 2019, 54, 1900580.	3.1	21
49	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration–Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 253-254.	1.0	5
50	Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	10
51	Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	26
52	Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs. <i>Clinical Mass Spectrometry</i> , 2019, 14, 34-45.	1.9	17
53	Predictors for treatment outcomes among patients with drug-susceptible tuberculosis in the Netherlands: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2019, 25, 761.e1-761.e7.	2.8	14
54	Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	8

#	ARTICLE	IF	CITATIONS
55	Lack of penetration of amikacin into saliva of tuberculosis patients. <i>European Respiratory Journal</i> , 2018, 51, 1702024.	3.1	9
56	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702490.	3.1	7
57	Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis - An update. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 17-25.	0.3	26
58	<i>In Vitro</i> Susceptibility of <i>Mycobacterium tuberculosis</i> to Amikacin, Kanamycin, and Capreomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	22
59	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 265-275.	5.2	80
60	Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 17-37.	1.0	37
61	Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S327-S335.	2.9	53
62	Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S303-S307.	2.9	26
63	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet</i> , 2018, 392, 821-834.	6.3	452
64	Variability and cost implications of three generations of the Roche LightCycler® 480. <i>PLoS ONE</i> , 2018, 13, e0190847.	1.1	5
65	Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 376-378.	0.6	1
66	Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	10
67	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	3.1	233
68	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601612.	3.1	16
69	Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601724.	3.1	20
70	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 688-694.	1.1	35
71	Neurological and functional recovery in tuberculosis patients with spinal cord injury in The Netherlands. <i>NeuroRehabilitation</i> , 2017, 40, 439-445.	0.5	8
72	Membrane Filtration Is Suitable for Reliable Elimination of <i>Mycobacterium tuberculosis</i> from Saliva for Therapeutic Drug Monitoring. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3292-3293.	1.8	12

#	ARTICLE	IF	CITATIONS
73	Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 11-21.	2.0	19
74	Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. <i>Clinical Infectious Diseases</i> , 2016, 62, civ921.	2.9	38
75	Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C₂h₂ measurements. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1695-1696.	0.6	3
76	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. <i>PLoS ONE</i> , 2016, 11, e0149768.	1.1	25
77	Implementing tuberculosis entry screening for asylum seekers: the Groningen experience. <i>European Respiratory Journal</i> , 2016, 48, 261-264.	3.1	21
78	Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. <i>European Respiratory Journal</i> , 2016, 48, 1800-1802.	3.1	9
79	Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2691-2703.	1.3	28
80	Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3942-3947.	1.4	12
81	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR-ÂandÂXDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1758-1766.	3.1	69
82	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. <i>European Respiratory Journal</i> , 2016, 48, 1230-1233.	3.1	5
83	Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. <i>International Journal of Mycobacteriology</i> , 2016, 5, S44-S45.	0.3	11
84	Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. <i>European Respiratory Journal</i> , 2016, 48, 1237-1239.	3.1	8
85	Statin Adjunctive Therapy for Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7004-7004.	1.4	7
86	Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV. <i>European Respiratory Journal</i> , 2016, 48, 932-934.	3.1	8
87	Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1025-1037.	1.3	19
88	Reply to Verhaeghe et al: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 146-147.	2.9	0
89	Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 517-518.	0.6	4
90	Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. <i>European Respiratory Journal</i> , 2016, 47, 1867-1869.	3.1	59

#	ARTICLE	IF	CITATIONS
91	End TB with precision treatment!. European Respiratory Journal, 2016, 47, 680-682.	3.1	45
92	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	2.9	34
93	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 2016, 47, 1235-1243.	3.1	92
94	Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. European Respiratory Journal, 2016, 47, 1229-1234.	3.1	30
95	High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015. PLoS ONE, 2016, 11, e0154791.	1.1	30
96	Evaluation of macrolides for possible use against multidrug-resistant <i>Mycobacterium tuberculosis</i> . European Respiratory Journal, 2015, 46, 444-455.	3.1	20
97	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. European Respiratory Journal, 2015, 45, 569-571.	3.1	20
98	Breakpoints and Drug Exposure Are Inevitably Closely Linked. Antimicrobial Agents and Chemotherapy, 2015, 59, 1384-1384.	1.4	5
99	The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincerâ„¢ family. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 8-15.	2.0	50
100	Determination of Bedaquiline in Human Serum Using Liquid Chromatography-Tandem Mass Spectrometry. Antimicrobial Agents and Chemotherapy, 2015, 59, 5675-5680.	1.4	28
101	Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis, 2015, 7, 481-495.	0.6	21
102	The Never Ending Struggle Against Development of Drug Resistance. Clinical Infectious Diseases, 2015, 61, 137-138.	2.9	0
103	Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future. Antimicrobial Agents and Chemotherapy, 2015, 59, 2474-2474.	1.4	7
104	Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2015, 46, 332-337.	1.1	28
105	Strategy To Limit Sampling of Antituberculosis Drugs Instead of Determining Concentrations at Two Hours Postingestion in Relation to Treatment Response. Antimicrobial Agents and Chemotherapy, 2014, 58, 628-628.	1.4	4
106	Optimization of Standard In-House 24-Locus Variable-Number Tandem-Repeat Typing for <i>Mycobacterium tuberculosis</i> and Its Direct Application to Clinical Material. Journal of Clinical Microbiology, 2014, 52, 1338-1342.	1.8	27
107	Raltegravir and rifampicin in patients with HIV and tuberculosis. Lancet Infectious Diseases, The, 2014, 14, 1046-1047.	4.6	3
108	Comparison of 14 Molecular Assays for Detection of <i>Mycobacterium tuberculosis</i> Complex in Bronchoalveolar Lavage Fluid. Journal of Clinical Microbiology, 2013, 51, 3505-3511.	1.8	19

#	ARTICLE	IF	CITATIONS
109	Drug concentration in lung tissue in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 1750-1752.	3.1	23
110	<i>Mycobacterium bovis</i> infection in a young Dutch adult: transmission from an elderly human source?. <i>Medical Microbiology and Immunology</i> , 2012, 201, 397-400.	2.6	4
111	Microevolution of <i>Mycobacterium tuberculosis</i> in a Tuberculosis Patient. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3813-3816.	1.8	65
112	Monitoring during and after tuberculosis treatment. , 0, , 308-325.		1